Alpha-Lipoic Acid https://greenmedinfo.com/category/keywords/Alpha-Lipoic%20Acid en A treatment approach including intravenous α-lipoic acid and low-dose naltrexone led to stable disease in this patient. https://greenmedinfo.com/article/treatment-approach-including-intravenous-lipoic-acid-and-low-dose-naltrexone-l n/a PMID:  Integr Cancer Ther. 2017 Dec 1:1534735417747984. Epub 2017 Dec 1. PMID: 29258346 Abstract Title:  The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenousα-Lipoic Acid/Low-Dose Naltrexone Protocol. Abstract:  In this case report, we describe the treatment of a 64-year-old male patient diagnosed with metastatic renal cell carcinoma (RCC) in June of 2008. In spite of a left nephrectomy and the standard oncological protocols, the patient developed a solitary left lung metastasis that continued to grow. He was informed that given his diagnosis and poor response to conventional therapy, any further treatment would, at best, be palliative. The patient arrived at the Integrative Medical Center of New Mexico in August of 2010. He was in very poor health, weak, and cachectic. An integrative program-developed by one of the authors using intravenous (IV)α-lipoic acid, IV vitamin C, low-dose naltrexone, and hydroxycitrate, and a healthy life style program-was initiated. From August 2010 to August 2015, the patient's RCC with left lung metastasis was followed closely using computed tomography and positron emission tomography/computed tomography imaging. His most recent positron emission tomography scan demonstrated no residual increased glucose uptake in his left lung. After only a few treatments of IV α-lipoic acid and IV vitamin C, his symptoms began to improve, and the patient regained his baseline weight. His energy and outlook improved,and he returned to work. The patient had stable disease with disappearance of the signs and symptoms of stage IV RCC, a full 9 years following diagnosis, with a gentle integrative program, which is essentially free of side effects. As of November 2017 the patient feels well and is working at his full-time job. https://greenmedinfo.com/article/treatment-approach-including-intravenous-lipoic-acid-and-low-dose-naltrexone-l#comments Alpha-Lipoic Acid Kidney Cancer Vitamin C: Intravenous Chemopreventive Chemotherapeutic Alpha-Lipoic Acid Chemopreventive Chemotherapeutic Kidney Cancer Vitamin C: Intravenous Human: Case Report Wed, 17 Jan 2018 17:13:05 +0000 greenmedinfo 158499 at https://greenmedinfo.com Alpha-lipoic acid can improve plasma adiponectin levels and may play a potential role in the treatment of metabolic risk factor in patients with schizophrenia. https://greenmedinfo.com/article/alpha-lipoic-acid-can-improve-plasma-adiponectin-levels-and-may-play-potential n/a PMID:  J Med Food. 2017 Jan ;20(1):79-85. Epub 2016 Dec 23. PMID: 28009525 Abstract Title:  Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia. Abstract:  Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and anti-inflammatory properties and is suggested to be a biomarker of metabolic disturbances. The aim of this study was to investigate the effects of alpha-lipoic acid (ALA) on plasma adiponectin and some metabolic risk factors in patients with schizophrenia. The plasma adipokine levels (adiponectin and leptin), routine biochemical and anthropometric parameters, markers of oxidative stress, and the serum phospholipid fatty acid profile in eighteen schizophrenic patients at baseline, in the middle, and at the end of a 3-month long supplementation period with ALA (500 mg daily) were determined. A significant increase in the plasma adiponectin concentrations, as well as a decrease in fasting glucose and aspartate aminotransferase activity (AST), was found. Baseline AST activity was independently correlated with the adiponectin concentrations. Our data show thatALA can improve plasma adiponectin levels and may play a potential role in the treatment of metabolic risk factor in patients with schizophrenia. Future randomized controlled trials are needed to confirm these preliminary investigations. https://greenmedinfo.com/article/alpha-lipoic-acid-can-improve-plasma-adiponectin-levels-and-may-play-potential#comments Adiponectin: Low Levels Alpha-Lipoic Acid Schizophrenia Adiponectin upregulation Hypoglycemic Agents Adiponectin upregulation Adiponectin: Low Levels Alpha-Lipoic Acid Hypoglycemic Agents Schizophrenia Human Study Tue, 11 Jul 2017 21:20:10 +0000 greenmedinfo 150298 at https://greenmedinfo.com Alpha-lipoic acid treatment improves vision-related quality of life in patients with dry age-related macular degeneration. https://greenmedinfo.com/article/alpha-lipoic-acid-treatment-improves-vision-related-quality-life-patients-dry- n/a PMID:  Tohoku J Exp Med. 2016 ;240(3):209-214. PMID: 27840374 Abstract Title:  α-Lipoic Acid Treatment Improves Vision-Related Quality of Life in Patients with Dry Age-Related Macular Degeneration. Abstract:  Dry form of age-related macular degeneration (AMD) constitutes 90% of AMD cases, and it is characterized by the formation of drusen under the retina and the slow breakdown of the light-sensing cells in the macula, which causes a gradual loss of central vision. Since oxidative stress is involved in the pathogenesis of dry AMD,α-lipoic acid (LA) with antioxidant properties was selected, and its effect on anti-oxidative markers and visual quality in patients with dry AMD was assessed. A total of 100 dry AMD patients (60-83 years old) were randomly assigned to LA treatment group (n = 50) and placebo control group (n = 50).We measured the serum superoxide dismutase (SOD) activity, an important marker of antioxidant defense, best-corrected visual acuity (BCVA), contrast sensitivity, and Chinese-Version Low Vision Quality of Life (CLVQOL) before and after LA or placebo intervention. Pearson correlation coefficients were calculated to explore the relationship between contrast sensitivity values and CLVQOL scores. There was a statistically significant increase in serum SOD activity after LA intervention. The CLVQOL score was improved significantly after LA treatment. The contrast sensitivity measured at middle andlow spatial frequency was significantly higher after LA treatment. CLVQOL scores were positively correlated with contrast sensitivity at low spatial frequency (3 cyc/degree) in LA-treated group. These results indicate that LA treatment improves vision-related quality of life in patients with dry AMDprobably by increasing antioxidant activity. Thus, LA can be regarded as a promising agent for the treatment of AMD. https://greenmedinfo.com/article/alpha-lipoic-acid-treatment-improves-vision-related-quality-life-patients-dry-#comments Alpha-Lipoic Acid Macular Degeneration Superoxide Dismutase Up-regulation Alpha-Lipoic Acid Macular Degeneration Superoxide Dismutase Up-regulation Human Study Tue, 11 Jul 2017 22:22:22 +0000 greenmedinfo 150310 at https://greenmedinfo.com The antioxidant cofactor alpha-lipoic acid may control endogenous formaldehyde metabolism in mammals. https://greenmedinfo.com/article/antioxidant-cofactor-alpha-lipoic-acid-may-control-endogenous-formaldehyde-met n/a PMID:  Front Neurosci. 2017 ;11:651. Epub 2017 Dec 1. PMID: 29249928 Abstract Title:  The Antioxidant Cofactor Alpha-Lipoic Acid May Control Endogenous Formaldehyde Metabolism in Mammals. Abstract:  The healthy human body contains small amounts of metabolic formaldehyde (FA) that mainly results from methanol oxidation by pectin methylesterase, which is active in a vegetable diet and in the gastrointestinal microbiome. With age, the ability to maintain a low level of FA decreases, which increases the risk of Alzheimer's disease and dementia. It has been shown that 1,2-dithiolane-3-pentanoic acid or alpha lipoic acid (ALA), a naturally occurring dithiol and antioxidant cofactor of mitochondrialα-ketoacid dehydrogenases, increases glutathione (GSH) content and FA metabolism by mitochondrial aldehyde dehydrogenase 2 (ALDH2) thus manifests a therapeutic potential beyond its antioxidant property. We suggested that ALA can contribute to a decrease in the FA content of mammals by acting on ALDH2 expression. To test this assumption, we administered ALA in mice in order to examine the effect on FA metabolism and collected blood samples for the measurement of FA. Our data revealed that ALA efficiently eliminated FA in mice. Without affecting the specific activity of FA-metabolizing enzymes(ADH1, ALDH2, and ADH5), ALA increased the GSH content in the brain and up-regulated the expression of the FA-metabolizing ALDH2 gene in the brain, particularly in the hippocampus, but did not impact its expression in the liver in vivo or in rat liver isolated from the rest of the body. After ALA administration in mice and in accordance with the increased content of brain ALDH2 mRNA, we detected increased ALDH2 activity in brain homogenates. We hypothesized that the beneficial effects of ALA on patients with Alzheimer's disease may be associated with accelerated ALDH2-mediated FA detoxification and clearance. https://greenmedinfo.com/article/antioxidant-cofactor-alpha-lipoic-acid-may-control-endogenous-formaldehyde-met#comments Alpha-Lipoic Acid Alzheimer's Disease Detoxifier Formaldehyde Neuroprotective Agents Alpha-Lipoic Acid Alzheimer's disease Detoxifier Gene Expression Regulation Neuroprotective Agents Animal Study Wed, 17 Jan 2018 17:43:50 +0000 greenmedinfo 158502 at https://greenmedinfo.com